Table 2 Comparison of PD and NPD using landmark analysis at 3Â months
Characteristics | PD Group N (%) n = 49 | NPD Group N (%) n = 39 | p-value |
|---|---|---|---|
Mean age, years (SD) | 66 (10.20) | 64 (9.61) | 0.401 |
Male Gender | 33 (67) | 33 (85) | 0.107 |
ECOG PS | Â | Â | 0.106 |
 0 | 23 (52) | 10 (27) | |
 1 | 15 (34) | 18 (49) | |
  > 2 | 6 (14) | 9 (24) | |
IMDC Risk Group | Â | Â | 0.139 |
 Favorable | 8 (17) | 4 (10) | |
 Intermediate | 35 (73) | 24 (63) | |
 Poor | 5 (10) | 10 (26) | |
Prior Nephrectomy | 35 (97) | 30 (97) | 1.000 |
No of prior systemic therapies, median, No. (range) | |||
No of prior systemic therapies | Â | Â | 0.404 |
 1 | 25 (51) | 15 (38) | |
 2 | 10 (20) | 14 (36) | |
 3 | 10 (20) | 6 (15) | |
  > 4 | 3 (6) | 4 (10) | |
Common prior systemic therapies | |||
 Sunitinib | 38 (78) | 24(61) | 0.161 |
 Pazopanib | 15 (31) | 15 (38) | 0.586 |
 Axitinib | 18 (37) | 17 (44) | 0.665 |
Sites of metastases at baseline | |||
 Brain | 7 (18) | 7 (14) | 0.862 |
 Bones | 13 (33) | 24 (49) | 0.208 |
 Lungs | 33 (85) | 31 (63) | 0.046 |
 Liver | 14 (36) | 12 (24) | 0.352 |
 Lymph Nodes | 31 (79) | 26 (53) | 0.019 |
 Pleural | 13 (33) | 5 (10) | 0.016 |
 Adrenal | 9 (23) | 11 (22) | 1.000 |